Dr Reddy's get USFDA nod for acute migraine injection

It is the firm's first branded neurological product, will be marketed in US by its wholly-owned specialty company

Dr Reddy's Laboratories has received the US Food and Drug Administration (USFDA) nod for ZembraceSymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine in adults.

The product is available as a pre-filled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan. The injection is intended to be given subcutaneously .

This is the first branded product in the company's neurology portfolio. It will be marketed in the United States by Promius Pharma, a wholly-owned specialty company of Dr Reddy's Laboratories.

"This is a major milestone for the company as we continue to bring innovative medicines to patients and physicians," G V Prasad, CEO and co-chairman, Dr Reddy's Laboratories, stated in a release.